/24-7PressRelease/ - NEW YORK, NY, October 11, 2006 - Insomnia is one of the most popular diseases found amongst majority of people in the U.S. According to a national survey conducted by the American Academy of Nurse Practitioners (AANP), "people living with insomnia despite evidence that it can have a serious, negative impact on overall health. The survey also shows that adults with insomnia live with the condition for an average of nearly six years before seeking help."
Insomnia or sleeping disorders can be treated effectively with medications such as rozerem that has controlled substances or drugs that have certain government restrictions imposed on it partly because of its potential or being addictive.
Some of the new sleep drugs can even cause very few side effects to treat insomnia. Benzodiazepines that includes Valium, Xanax and Halcion which may carry a risk of abuse, addiction or cognitive impairment. Rozerem does not create such side effects because it works through a different pathway in the brain - one that involves melatonin receptors - than benzodiazepines do.
Rozerem has proved to help people fall asleep fast and to help them wake up without feeling that groggy, "hung over" feeling. Once a physician has prescribed to take a sleeping pill or sedatives and anti anxiety drugs, one has to take these regularly. However, newer drugs such as Zolpidem, Lunesta, and Rozerem have been prescribed in millions at least in part to an advertising blitz from their manufacturers.
Please do visit http://www.benzer11.com/rozerem.html to know more about sleep aid medications and approved treatments.
Benzer11.com has a team of committed pharmacists who are quite professional for their principals and values and lead a team of branch colleagues within their community.
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
- aid, buy, drug, effects, insomnia, medication, pill, rozerem, side, sleep, sleeping
Read more Press Releases from Olivia Andrews:Other Press Release Headlines:
